Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll PARP inhibition: PARP1 and beyond Rouleau M; Patel A; Hendzel MJ; Kaufmann SH; Poirier GGNat Rev Cancer 2010[Apr]; 10 (4): 293-301Recent findings have thrust poly(ADP-ribose) polymerases (PARPs) into the limelight as potential chemotherapeutic targets. To provide a framework for understanding these recent observations, we review what is known about the structures and functions of the family of PARP enzymes, and then outline a series of questions that should be addressed to guide the rational development of PARP inhibitors as anticancer agents.|Animals[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Cell Death[MESH]|DNA Damage[MESH]|DNA, Neoplasm/genetics[MESH]|Dacarbazine/analogs & derivatives/therapeutic use[MESH]|Deoxycytidine/analogs & derivatives/therapeutic use[MESH]|Gemcitabine[MESH]|Humans[MESH]|Kinetics[MESH]|Mice[MESH]|Neoplasms/enzymology/pathology[MESH]|Poly (ADP-Ribose) Polymerase-1[MESH]|Poly(ADP-ribose) Polymerase Inhibitors[MESH]|Poly(ADP-ribose) Polymerases/genetics/metabolism/*therapeutic use[MESH]|Substrate Specificity[MESH]|Temozolomide[MESH] |